KTTA

Pasithea Therapeutics Corp.

Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001841330 Biotech & Drug Discovery

$0.4050 −0.04 (−8.99%)

Oct 23 4:00 PM ET · prev $0.4450

Market cap

$14.9M

Nano cap

Median target

$3.00

+641% · range $3.00–3.00

Next earnings

Nov 11

in 16 days

1 year

−42.8%

from $0.7080 · Oct 27

30 days

−15.6%

from $0.4800

52-week range

$0.2920–1.47

−72% from high · low Nov 21

Avg volume 20D

227.7K

Oct 23 spike 1.53M

Short interest

🔒 Subscribers only

Insider net

+$53.0K

1 buyer · 0 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read MIXED 2 reports · 90 days

Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score

Avg score

·High conf. 1/2 ·Next Earnings date, Nov 11, 2026

Strongest NEUTRAL Pasithea Therapeutics announced it will present initial clinical data from its ongoing Phase 1/1b trial of…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

B Jun 17 1 insider buy $53.0K at $0.5300
X Aug 14 Short interest jumps 29.2% to 253.9K
E Sep 14 FDA: Pasithea Therapeutics Announces Presentation of Initial PA…
X Sep 30 Short interest falls 40.8% to 159.8K

Signal stack

Where each data set points today.

InsidersBULLISH

1 insider bought $53.0K at an average $0.5300. No open-market sales. Price is 24% below their cost.
InstitutionsBULLISH

Q2 2026: 4 added (0 new), 1 trimmed or exited.
TrendDOWNTREND

19% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

Fund	Move	Shares	Value
AMERIPRISE FINANCIAL INC	ADD	1,864,485	$961.0K
UBS Group AG	DOUBLED	188,111	$96.9K
VANGUARD CAPITAL MANAGEMENT LLC	DOUBLED	126,279	$65.0K
RENAISSANCE TECHNOLOGIES LLC	TRIM	65,600	$33.8K
NORTHERN TRUST CORP	ADD	31,405	$16.2K
AMERIPRISE FINANCIAL INC	TRIM	1,350,896	$1.0M
GEODE CAPITAL MANAGEMENT, LLC	ADD	103,985	$77.1K
UBS Group AG	ADD	26,149	$19.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Jun 2026

12-month targets · 1 analysts

$0.4050 $3.00 $3.00 $3.00

Price is below the lowest target. Median implies +641%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Jun 16, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy

Insider ledger

Form 4

$53.0K

bought · 1 insider

sold · 0 insiders

−23.6%

vs their $0.5300 cost

Date	Insider	Type	Value
Jun 17, 2026	Coastlands Capital LP 10%+ Owner	BUY	$53.0K
May 1, 2026	Novak Alfred J Director	AWARD	152,783 sh
May 1, 2026	Leahy Emer Director	AWARD	152,783 sh
May 1, 2026	Dumesnil Simon Director	AWARD	152,783 sh
May 1, 2026	Krishnan Kartik Chief Medical Officer	AWARD	1,129,323 sh
May 1, 2026	Schneiderman Daniel H Chief Financial Officer	AWARD	1,129,323 sh
May 1, 2026	STEINMAN LAWRENCE Director	AWARD	152,783 sh
May 1, 2026	Marques Tiago Chief Executive Officer	AWARD	1,756,069 sh

Earnings setup

Estimates

Nov 11

reports in 16 days

Revision history: 🔒 Fresh data, subscribers only

Period	EPS est.	Range	30D rev.	Revenue
Current Q	🔒 Fresh data, subscribers only
Next Q	🔒 Fresh data, subscribers only
Current FY	🔒 Fresh data, subscribers only
Next FY	🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026

🔒 Subscribers only

shares short

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Sep 16, 2026 SEC

Pasithea Therapeutics announced that its publicly traded warrants (KTTAW) will expire on September 17, 2026, and will…

8-K — Impact 3/10

Sep 14, 2026 Press

Pasithea Therapeutics announced it will present initial clinical data from its ongoing Phase 1/1b trial of PAS-004 in…

Impact 4/10

Sep 14, 2026 FDA

Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference

Pasithea Tx to Present Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult

Jun 30, 2026 Inst.

AMERIPRISE FINANCIAL INC — ADD

1,864,485 shares ($961.0K)

Jun 30, 2026 Inst.

UBS Group AG — DOUBLED

188,111 shares ($96.9K)

Jun 17, 2026 Insider

Coastlands Capital LP bought 100,000 shares

10%+ Owner @ $0.5300 ($53.0K)

May 1, 2026 Insider

Novak Alfred J was granted 152,783 shares